Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 31,346 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Study participants Clear all

Conditions: Nail Diseases
Interventions: Suzetrigine, Oxycodone/Acetaminophen, Acetaminophen, Ibuprofen; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Local Anaesthetic Complication, Pain
Interventions: Kinetic Anesthesia Device, Control; Device · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung, Sensitizing EGFR Gene Mutation
Interventions: Etrumadenant, Zimberelimab, Carboplatin, Pemetrexed, Pembrolizumab; Drug
Lead sponsor: Arcus Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 8
States / cities: Tucson, Arizona • Fort Myers, Florida • Tavares, Florida + 5 more

Conditions: Alzheimer s Disease, MCI With Increased Risk for Alzheimer Disease
Interventions: Ultrasonic Debris Clearance, sham; Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus
Interventions: Structured Group Exercise; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Non-Hodgkin's Lymphoma
Interventions: Glofitamab, Obinutuzumab, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 940 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 6
States / cities: Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more

Conditions: Multiple Myeloma
Interventions: Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II; Drug · Behavioral · Biological
Lead sponsor: University of Arkansas; Other
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Healthy
Interventions: Placebo, Flavonoids, Flavonoids+Prebiotics; Other · Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Primary Biliary Cholangitis
Interventions: Elafibranor, Placebo; Drug · Other
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 20
States / cities: Coronado, California • Los Angeles, California • Sacramento, California + 16 more

Conditions: Alzheimer's Disease, Healthy Volunteer
Interventions: [11C]RO6924963, [11C]RO6931643, [18F]RO6958948; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 25 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: PTSD
Interventions: Transcendental Meditation (TM), Present Centered Therapy (PCT); Behavioral
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: La Jolla, California • Los Angeles, California • Palo Alto, California + 2 more

Conditions: Cigarette Smoking
Interventions: Quest; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 246 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma, Asthma Attack, Asthma Exacerbations
Interventions: Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application; Drug · Other
Lead sponsor: DARTNet Institute; Government
Eligibility: 13 Years to 75 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more

Conditions: Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Interventions: Anifrolumab, Anifrolumab; Combination Product · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 5 Years to 80 Years
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 21
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 18 more

Conditions: Alzheimer Disease
Interventions: LY3439539; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Irvine, California • Long Beach, California • Los Angeles, California + 5 more

Conditions: Stress Urinary Incontinence
Interventions: Vaginal pessary; Device
Lead sponsor: Liv Labs Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Chicago, Illinois • Lake Forest, Illinois • Columbus, Ohio

Conditions: Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
Interventions: Sofosbuvir, RBV; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 8
States / cities: San Francisco, California • Indianapolis, Indiana • Kansas City, Kansas + 4 more

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP); Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Healthy Participants
Interventions: Eptinezumab Mammalian Cell Line, Eptinezumab Yeast Cell Line; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Daytona Beach, Florida • Madison, Wisconsin

Conditions: PTSD and Trauma-related Symptoms
Interventions: Preparatory Session, Ketamine-assisted Psychotherapy Session #1, Ketamine-assisted Psychotherapy Session #2, Integration Session; Behavioral · Drug
Lead sponsor: Irma Fleming; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lung Cancer
Interventions: semi-structured interviews; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Nutrition, Healthy, Dyslipidemia, Overweight and Obesity
Interventions: Pecan, Control; Other
Lead sponsor: University of Georgia; Other
Eligibility: 25 Years to 75 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: COPD
Interventions: SpiroPD; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Post-op Analgesia of Nail Unit Procedures

Kinetic Anesthesia Device Study

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer

Ultrasonic Debris Clearance to Promote Brain Resilience

Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

Effects of Exercise in Combination With Epoetin Alfa

Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds

A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

Transcendental Meditation in Veterans and First Responders With PTSD

Use and Harm Exposure in New Low Nicotine Cigarettes

Individualizing Treatment for Asthma in Primary Care (Full Study)

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

A Study of LY3439539 in Participants With Alzheimer's Disease

Pippa Pessary Study (Clinical Trial)

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines

KALM-B: Ketamine-assisted Psychotherapy (KAP) to Lessen Morbidity After Burn Injury

Understanding Symptom Recognition and Treatment Decision-making in Hispanic/Latino Lung Cancer Patients

Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose

Feasibility of At-Home Handheld Spirometry